Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of blood pressure lowering in patients treated with intravenous thrombolysis before endovascular thrombectomy.
Yun J, Kim KH, Jung JW, Kim YD, Heo J, Lee H, Choi JK, Lim IH, Hong SH, Kim BM, Kim DJ, Shin NY, Cho BH, Ahn SH, Park H, Sohn SI, Hong JH, Song TJ, Chang Y, Kim GS, Seo KD, Lee K, Chang JY, Seo JH, Lee S, Baek JH, Cho HJ, Shin DH, Kim J, Yoo J, Baik M, Lee KY, Jung YH, Hwang YH, Kim CK, Kim JG, Lee CJ, Park S, Jeon S, Lee HS, Kwon SU, Lee IH, Bang OY, Heo JH, Nam HS. Yun J, et al. Among authors: cho bh. Int J Stroke. 2025 Jan 17:17474930251315630. doi: 10.1177/17474930251315630. Online ahead of print. Int J Stroke. 2025. PMID: 39819210
Graphene Quantum Dots as Antifibrotic Therapy for Kidney Disease.
Li L, Jin W, Kim J, Bae G, Yang SH, Cho B, Han SH, Lee J, Kim D, Kim DK, Lim CS, Hong BH, Lee JP. Li L, et al. Among authors: cho b. ACS Appl Bio Mater. 2025 Jan 15. doi: 10.1021/acsabm.4c01053. Online ahead of print. ACS Appl Bio Mater. 2025. PMID: 39814584
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib.
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Horinouchi H, et al. Among authors: cho bc. Ann Oncol. 2025 Jan 11:S0923-7534(25)00005-5. doi: 10.1016/j.annonc.2025.01.001. Online ahead of print. Ann Oncol. 2025. PMID: 39805351
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, Dagogo-Jack I, Bryan DS, Drazer MW, Forde P, Husain AN, Sauter JL, Rusch V, Bradbury PA, Cho BCJ, de Perrot M, Ghafoor A, Graham DL, Khorshid O, Lebensohn A, White J, Hassan R. Kindler HL, et al. Among authors: cho bcj. J Clin Oncol. 2025 Jan 8:JCO2402425. doi: 10.1200/JCO-24-02425. Online ahead of print. J Clin Oncol. 2025. PMID: 39778125
4,735 results